Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Innate Pharma
Research
Innate antibody pits NK cells against lymphoma in animal models
The antibody, called IPH6501, is now being evaluated in a phase 1/2 trial in patients with relapsed or unresponsive B cell non-Hodgkin lymphoma.
Darren Incorvaia
Nov 15, 2024 2:00pm
Less than a year in, BenevolentAI CEO is out—Chutes & Ladders
Oct 18, 2024 8:30am
Innate drops monotherapy plans for lacutamab in type of lymphoma
Mar 21, 2024 8:27am
Scorpion taps new CEO, CMO—Chutes & Ladders
Jan 5, 2024 9:30am
Innate secures speedy resolution of FDA hold on lymphoma trials
Jan 4, 2024 9:50am
Innate lymphoma trials put on partial hold after patient dies
Oct 5, 2023 6:20am
